Supriya Lifescience Gets WHO GMP Certification for Ambernath Facility
Supriya Lifescience’s Ambernath facility earns WHO GMP Certification, unlocking new opportunities in global formulations manufacturing and exports.
New Delhi | October 10, 2025: Supriya Lifescience Ltd., a well-known maker of Active Pharmaceutical Ingredients (APIs), has received the WHO GMP certification for its Ambernath facility. This marks an important step in the company’s growth plan.
With this approval, the site can now start making and selling formulations. It also confirms that Supriya Lifescience meets top global quality standards.
Supriya Lifescience WHO GMP Certification: A New Chapter
The Supriya Lifescience WHO GMP Certification opens the door to new opportunities. The Ambernath facility was built to expand the company’s work from APIs to finished formulations.
The site can make tablets, capsules, injectables, and inhalation products. At full capacity, it may earn around ₹500 crore in yearly revenue. The company also expects better profit margins than its current API business.
Expanding to Global Markets
The company’s annual report for FY 2024–25 called the Ambernath project a key growth plan. Now, with the WHO GMP approval, Supriya Lifescience can supply products to global and WHO-listed markets.
This move supports the company’s strategy to grow in the formulations segment. Along with its Lote Parshuram API site, Supriya now has over 1,020 KL of total manufacturing capacity. This gives it more flexibility and better use of its assets.
A Message from Leadership
Dr. Satish Wagh, Executive Chairman and Whole-Time Director of Supriya Lifescience Ltd., said:
“Getting the WHO GMP certification for Ambernath is a proud moment. It proves our quality and gives us the chance to grow faster in the formulations business. This achievement will help us reach new markets and create more value for our stakeholders.”
Innovation and Future Growth
The Ambernath site is more than just a manufacturing plant. It also supports research and development, pilot projects, and contract manufacturing (CDMO/CMO) work.
With the Supriya Lifescience WHO GMP Certification, the company can now focus more on:
- Stronger compliance and global standards
- Product innovation
- Long-term growth and value creation
About Supriya Lifescience
Supriya Lifescience Ltd. is a cGMP-compliant pharma company that makes and exports Active Pharmaceutical Ingredients and formulations. It serves customers in over 85 countries and continues to grow with a focus on quality and innovation.
The WHO GMP Certification for Supriya Lifescience’s Ambernath facility is a big achievement. It shows the company’s strong commitment to quality and its goal of becoming a leading player in the global formulations market.
This milestone strengthens Supriya Lifescience’s position as a trusted and growing name in the pharmaceutical industry.
Also Read : Supriya Lifescience Ltd. Reports Rs 145.07 Cr Revenue and 35.6% EBITDA Margin in Q1 FY26
